Abstract
Communicable diseases remain a leading cause of death and disability in low- and middle-income countries (LMICs). mHealth technologies carry considerable promise for managing these disorders within resource-poor settings, but many existing applications simply represent digital versions of existing guidelines or clinical calculators, communication facilitators, or patient self-management tools.
We thus systematically searched PubMed, Web of Science, and Cochrane Central for studies published between January 2007 and October 2019 involving technologies that were mobile phone- or tablet-based; able to screen for, diagnose, or monitor a communicable disease of importance in LMICs; and targeted health professionals as primary users. We excluded technologies that merely digitized existing paper-based tools or simply facilitated communication. Extracted data included disease category, pathogen type, diagnostic method, intervention purpose, study/target population, sample size, study methodology, development stage, accessory requirement, country of development, operating system, and cost. Given the search timeline and the extremely rapid turnover in the science concerning Coronavirus Disease 2019 and its novel variants, studies involving it were not included in the analysis.
Of 13,262 studies identified by the screen, 33 met inclusion criteria. 12% were randomized clinical trials (RCTs), with 58% of publications representing technical descriptions. 62% of studies had 100 or fewer subjects. All studied technologies involved diagnosis or screening steps; none addressed the monitoring of infections. 52% focused on priority diseases (HIV, malaria, tuberculosis), but only 12% addressed a neglected tropical disease. Although most reported studies were priced under 20USD at time of publication, two thirds of the records did not yet specify a cost for the study technology.
We conclude that there are only a small number of mHealth technologies focusing on innovative methods of screening and diagnosing communicable diseases potentially of use in LMICs. Rigorous RCTs, analyses with large sample size, and technologies assisting in the monitoring of diseases are needed.
Author Summary Although significant progress has been made in decreasing their worldwide impact, infectious diseases still represent a considerable burden of disease and death. This is especially the case in certain regions of low- and middle-income countries, where limited healthcare resources, personnel, and facilities can make it difficult to provide high quality care. Mobile health (mHealth) technologies are disruptive tools that hold considerable promise in these resource-constrained settings by circumventing some of the aforementioned obstacles.
To better understand the availability and characteristics of mHealth technologies for use in low- and middle-income countries, we systematically searched for studies published in English between January 2007 through October 2019 to identify all existing mobile phone- or tablet-based innovations targeted at healthcare providers for use against infectious diseases in these settings and summarized their qualities and performance.
We found that four times as many publications focused on tools that simply made data transfer more simple than there were on new tools for detecting or monitoring diseases. Few studies were tested under the most rigorous scientific methods. Many diagnostic technologies we identified require specialized attachments or additional laboratory equipment that connect to the smartphone or tablet, which could make their use in some settings more challenging.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=193945
Funding Statement
None.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos